人乳头瘤病毒HPV6b重组减毒沙门菌粘膜免疫的效果测定

Efficiency of Mucosal Immunization with Recombinant Attenuated Salmonella typhimurium Vector Vaccine of Human Papilloma Virus Type 6b

为观察人乳头瘤病毒 6b型 (HPV6b )的重组减毒沙门菌载体疫苗粘膜免疫小鼠的免疫效果及探讨研制治疗尖锐湿疣的治疗性粘膜疫苗的机制 ,我们用构建的HPV6b重组减毒沙门菌粘膜免疫BALB/c小鼠 ,检测了阴道冲洗液中特异的SIgA、血清中IgG、T淋巴细胞增殖以及载体疫苗在机体内的稳定性。结果表明 ,粘膜免疫后 ,实验组与对照组相比较 ,阴道冲洗液中抗HPV6bL1的SIgA差异显著 ,实验组血清中抗HPV6bL1IgG水平低 ,T淋巴细胞增殖明显 ,疫苗在小鼠体内持续存在4 0d以上。研究结果提示我们所构建的重组减毒沙门菌粘膜免疫小鼠后 ,阴道粘膜局部能分泌特异的抗人乳头瘤病毒HPV6bSIgA ,也能激发细胞免疫 ,且此疫苗在小鼠体内能稳定存在。

In order to observe the efficiency of mucosal immunization with recombimant attenuated Salmonella typhimurium vector vaccine of human papilloma virus type 6b (HPV6b) and to study the related mechanism in regard to the therapeutic usage of the vaccine for the treatment of condylomata accuminata,mice were mucosally immunized the recombinant attenated Salmonella typhimurium vector vaccine,and the SIgA against HPV6b in the vaginal washings,IgG in sera,proliferation of T lymphocytes and stability of this vector vaccine in vivo were determined The results showed that after mucosal immunization the SIgA against HPV6b L1 in the vaginal washings of the experimental group of mice was significantly different from those of the control group,and the levels of anti HPV6b L1 IgG in sera of the body without loss of efficiency for more than 40 days It concludes that mucosal immunization with the recombinant attenuated Salmonella typhimurium vector vaccine can elicit the production of specific SIgA against HPV6b on vaginal mucosa and induce the development of cellular immunity